secwatch.observer — SEC 8-K summary
======================================

Issuer:     OSR Holdings, Inc. (OSRH)
CIK:        0001840425
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001213900-26-027984
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

OSR Holdings discloses Pexa-Vec license talks and potential SillaJen controlling stake
--------------------------------------------------------------------------------

- Vaximm in active negotiations with SillaJen to license Pexa-Vec, a Phase 2 oncolytic immunotherapy for renal cell carcinoma.
- OSR Holdings held preliminary verbal talks to acquire ~16% controlling stake in SillaJen (KOSDAQ:215600).
- No binding term sheet, letter of intent, or definitive agreement exists for either matter.
- Disclosed to comply with Regulation FD after inadvertent reference during March 13 analyst call.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840425/000121390026027984/0001213900-26-027984-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840425/000121390026027984/ea0281786-8k_osr.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-027984

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer